MDT
Medtronic plc
$82.01
-1.82 (-2.17%)
At close · Jul 8
Market Cap
$104.98B
Shares
1,280,045,190
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$36.36B
+8.4%
FY2026
Net Income
$4.8B
+3%
FY2026
Gross Margin
12.91%
-5.6pp
FY2020
Operating Margin
17.78%
0pp
FY2026
Diluted EPS
$3.73
+3.3%
FY2026
Operating Cash Flow
$7.33B
+4.1%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2027 (G) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B | $30.12B | $28.91B | $30.56B | $29.95B | $29.71B | $28.83B | $20.26B | |
| — | $383M | $511M | $597M | $386M | — | — | — | — | — | — | — | — | |
| — | $12.72B | $11.63B | $11.22B | $10.72B | $10.15B | $10.48B | $9.42B | $9.16B | $9.06B | $9.29B | $9.14B | $6.31B | |
| — | — | — | — | — | — | — | $3.73B | $5.66B | $20.9B | $20.42B | $19.69B | $13.95B | |
| — | — | — | — | — | — | — | 12.91% | 18.53% | 69.77% | 68.73% | 68.29% | 68.86% | |
| — | $2.87B | $2.73B | $2.74B | $2.7B | $2.75B | $2.49B | $2.33B | $2.33B | $2.25B | $2.19B | $2.22B | $1.64B | |
| — | $11.78B | $10.85B | $10.74B | $10.42B | $10.29B | $10.15B | $10.11B | $10.42B | $9.97B | $9.71B | $9.47B | $6.9B | |
| — | $1.77B | $1.81B | $1.69B | $1.7B | $1.73B | $1.78B | $1.76B | $1.76B | $1.82B | $1.98B | $1.93B | $733M | |
| — | $2.96B | $2.86B | $2.65B | $2.7B | $2.71B | $2.7B | $2.66B | $2.66B | $2.64B | $2.92B | $2.82B | $1.31B | |
| — | — | $300M | $389M | $564M | $354M | — | — | — | — | — | — | — | |
| — | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B | $4.48B | $4.79B | $6.27B | $6.65B | $5.33B | $5.29B | $3.77B | |
| — | 17.78% | 17.76% | 15.89% | 17.56% | 18.15% | 14.89% | 16.57% | 20.51% | 22.2% | 17.94% | 18.35% | 18.59% | |
| — | $9.43B | $8.82B | $7.79B | $8.18B | $8.46B | $7.19B | $7.45B | $8.93B | $9.3B | $8.25B | $8.11B | $5.07B | |
| — | $715M | $729M | $719M | $636M | $553M | $925M | $1.09B | $1.44B | $1.15B | $1.09B | $1.39B | $666M | |
| — | $384M | $402M | $412M | $515M | $318M | $336M | $356M | $373M | -$505M | -$222M | -$107M | -$118M | |
| — | $6.14B | $5.63B | $4.84B | $5.36B | $5.52B | $3.9B | $4.06B | $5.2B | $5.68B | $4.6B | $4.34B | $3.49B | |
| — | $1.3B | $936M | $1.13B | $1.58B | $456M | $265M | -$751M | $547M | $2.58B | $578M | $798M | $811M | |
| — | $4.8B | $4.66B | $3.68B | $3.76B | $5.04B | $3.61B | $4.79B | $4.63B | $3.1B | $4.03B | $3.54B | $2.68B | |
| — | 13.2% | 13.9% | 11.36% | 12.03% | 15.9% | 11.97% | 16.56% | 15.16% | 10.36% | 13.56% | 12.27% | 13.2% | |
| — | $37M | $29M | $28M | $26M | $22M | $24M | $17M | $19M | -$9M | -$4M | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $3.54B | $2.68B | |
| — | $4.98B | $3.7B | $3.86B | $2.52B | $6.26B | $3.68B | $3.94B | $3.66B | $4.13B | $3.28B | $2.85B | $2.09B | |
| USD/shares | — | $3.75 | $3.63 | $2.77 | $2.83 | $3.75 | $2.68 | $3.57 | $3.44 | $2.29 | $2.92 | $2.51 | $2.44 |
| USD/shares | $5.90 – $6.00* | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 | $2.66 | $3.54 | $3.41 | $2.27 | $2.89 | $2.48 | $2.41 |
| shares | — | 1.28B | 1.29B | 1.33B | 1.33B | 1.34B | 1.34B | 1.34B | 1.35B | 1.36B | 1.38B | 1.41B | 1.1B |
| shares | — | 1.29B | 1.29B | 1.33B | 1.33B | 1.35B | 1.35B | 1.35B | 1.36B | 1.37B | 1.39B | 1.43B | 1.11B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2026: $24.92B in buybacks, $34.95B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.67×
Medical Devices median 3.68×
EV/EBIT
20.62×
Medical Devices median 21.44×
P/E (TTM)
22.47×
Medical Devices median 26.54×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2026-04-24 | 2025-04-25 | 2024-04-26 | 2023-04-28 | 2022-04-29 | 2021-04-30 | 2020-04-24 | 2019-04-26 |
|---|---|---|---|---|---|---|---|---|
| Total Reportable Segments | $33,079,000,000 | $30,734,000,000 | $29,654,000,000 | $30,731,000,000 | $30,959,000,000 | — | — | — |
| Cardiovascular | $13,976,000,000 | $12,481,000,000 | $11,831,000,000 | $11,522,000,000 | $11,368,000,000 | $10,772,000,000 | $10,468,000,000 | — |
| Neuroscience Group | $10,287,000,000 | $9,846,000,000 | $9,406,000,000 | $8,959,000,000 | $8,784,000,000 | — | — | — |
| Medical Surgical | $8,815,000,000 | $8,407,000,000 | $8,417,000,000 | $7,989,000,000 | $8,469,000,000 | — | — | — |
| Other Operating Segments Including Diabetes | $3,247,000,000 | $2,892,000,000 | $2,710,000,000 | — | — | — | — | — |
| Diabetes Group | $3,112,000,000 | $2,755,000,000 | $2,488,000,000 | $2,262,000,000 | $2,338,000,000 | — | — | — |
| Other Operating Segment Misc | $135,000,000 | $137,000,000 | $221,000,000 | — | — | — | — | — |
| Cardiovascular Portfolio | — | — | — | — | — | — | — | $11,505,000,000 |
| Diabetes Operating Unit | — | — | — | $2,262,000,000 | $2,338,000,000 | $2,413,000,000 | $2,368,000,000 | $2,391,000,000 |
| Medical Surgical Portfolio | — | — | — | $8,433,000,000 | $9,141,000,000 | $8,737,000,000 | $8,352,000,000 | $8,478,000,000 |
| Neuroscience Portfolio | — | — | — | $8,959,000,000 | $8,784,000,000 | $8,195,000,000 | $7,725,000,000 | $8,183,000,000 |
| Other Segment | — | $137,000,000 | $221,000,000 | $495,000,000 | — | — | — | — |
| All Other Segments | — | $137,000,000 | $221,000,000 | $495,000,000 | $727,000,000 | — | — | — |
By Geography (USD)
| Component | 2026-04-24 | 2025-04-25 | 2024-04-26 | 2023-04-28 | 2022-04-29 | 2021-04-30 | 2020-04-24 | 2019-04-26 |
|---|---|---|---|---|---|---|---|---|
| Total Other Countries Excluding Ireland | $36,221,000,000 | $33,421,000,000 | $32,251,000,000 | $31,129,000,000 | $31,585,000,000 | $30,017,000,000 | $28,828,000,000 | $30,466,000,000 |
| Non Us | $18,261,000,000 | $16,365,000,000 | $15,802,000,000 | — | — | — | — | — |
| Total Other Countries Excluding United States and Ireland | $18,118,000,000 | $16,250,000,000 | $15,689,000,000 | $14,756,000,000 | $15,450,000,000 | $14,491,000,000 | $13,909,000,000 | $14,272,000,000 |
| United States | $18,103,000,000 | $17,171,000,000 | $16,562,000,000 | $16,373,000,000 | $16,135,000,000 | $15,526,000,000 | $14,919,000,000 | $16,194,000,000 |
| Ireland | $143,000,000 | $116,000,000 | $113,000,000 | $98,000,000 | $101,000,000 | $100,000,000 | $85,000,000 | $91,000,000 |
| International | — | $16,365,000,000 | $15,802,000,000 | $14,854,000,000 | — | — | — | — |
| Japan Australia New Zealand Korea Canadaand Western Europe | — | — | $9,979,000,000 | $9,408,000,000 | $10,126,000,000 | $9,815,000,000 | $9,287,000,000 | $9,631,000,000 |
| Middle East Africa Latin America Eastern Europeand Asia Excluding Japanand Korea | — | — | $5,823,000,000 | $5,446,000,000 | $5,426,000,000 | $4,777,000,000 | $4,707,000,000 | $4,732,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2026-04-24 | 2025-04-25 | 2024-04-26 | 2023-04-28 | 2022-04-29 | 2021-04-30 | 2020-04-24 | 2019-04-26 |
|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $3,672,000,000 | $3,344,000,000 | $3,078,000,000 | $4,522,000,000 | $4,596,000,000 | $3,850,000,000 | $3,719,000,000 | — |
| Neuroscience Group | $3,062,000,000 | $3,031,000,000 | $2,822,000,000 | $3,712,000,000 | $3,858,000,000 | — | — | — |
| Medical Surgical | $2,128,000,000 | $2,071,000,000 | $2,193,000,000 | $3,048,000,000 | $3,698,000,000 | — | — | — |
| Other Operating Segments Including Diabetes | $106,000,000 | $214,000,000 | $96,000,000 | — | — | — | — | — |
| Cardiac And Vascular Group | — | — | — | — | — | — | $3,719,000,000 | $4,532,000,000 |
| Cardiovascular Portfolio | — | — | — | — | — | $3,850,000,000 | $3,719,000,000 | $4,532,000,000 |
| Diabetes Group | — | $491,000,000 | $394,000,000 | $383,000,000 | $588,000,000 | — | $546,000,000 | $739,000,000 |
| Diabetes Operating Unit | — | — | — | $378,000,000 | $583,000,000 | $598,000,000 | $546,000,000 | $739,000,000 |
| Medical Surgical Portfolio | — | — | — | $2,856,000,000 | $3,572,000,000 | $3,021,000,000 | $3,044,000,000 | $3,262,000,000 |
| Minimally Invasive Therapies Group | — | — | — | — | — | — | $3,044,000,000 | $3,262,000,000 |
| Neuroscience Portfolio | — | — | — | $3,617,000,000 | $3,765,000,000 | $3,162,000,000 | $2,915,000,000 | $3,319,000,000 |
| Other Segment | — | $49,000,000 | $10,000,000 | -$89,000,000 | — | — | — | — |
| Restorative Therapies Group | — | — | — | — | — | — | $2,915,000,000 | $3,319,000,000 |
| All Other Segments | — | — | $10,000,000 | -$89,000,000 | -$31,000,000 | — | — | — |
Operating Margin by Segment (%)
| Component | 2026-04-24 | 2025-04-25 | 2024-04-26 | 2023-04-28 | 2022-04-29 | 2021-04-30 | 2020-04-24 | 2019-04-26 |
|---|---|---|---|---|---|---|---|---|
| Cardiovascular | 26.3% | 26.8% | 26% | 39.2% | 40.4% | 35.7% | 35.5% | — |
| Neuroscience Group | 29.8% | 30.8% | 30% | 41.4% | 43.9% | — | — | — |
| Medical Surgical | 24.1% | 24.6% | 26.1% | 38.2% | 43.7% | — | — | — |
| Other Operating Segments Including Diabetes | 3.3% | 7.4% | 3.5% | — | — | — | — | — |
| Diabetes Group | — | 17.8% | 15.8% | 16.9% | 25.1% | — | — | — |
| Cardiovascular Portfolio | — | — | — | — | — | — | — | 39.4% |
| Diabetes Operating Unit | — | — | — | 16.7% | 24.9% | 24.8% | 23.1% | 30.9% |
| Medical Surgical Portfolio | — | — | — | 33.9% | 39.1% | 34.6% | 36.4% | 38.5% |
| Neuroscience Portfolio | — | — | — | 40.4% | 42.9% | 38.6% | 37.7% | 40.6% |
| Other Segment | — | 35.8% | 4.5% | -18% | — | — | — | — |
| All Other Segments | — | — | 4.5% | -18% | -4.3% | — | — | — |